Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://lindseye946qwu3.wikifrontier.com/user